METASTATIC CANCER

This trial tests a precise type of radiation called SABR on all visible tumors in people with 11 or more metastases. Participants are randomly assigned to either standard palliative radiation or SABR to every tumor. The goal is to see if this aggressive approach improves overall …

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR)…

This study tests whether adding the experimental drug CGT9486 to the standard drug sunitinib helps people with advanced GIST live longer without their cancer growing. About 482 adults with GIST that cannot be removed by surgery or has spread will take part. The goal is to see if …

This phase 2 trial is testing three different drugs—abiraterone acetate, enzalutamide, and apalutamide—in 192 veterans with castrate-sensitive prostate cancer that has spread. The goal is to see which drug works best as a first treatment when combined with hormone therapy. Resear…

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…

This early-phase trial tests a radioactive drug called Y-NM600 in people with metastatic cancer who are already receiving immunotherapy (anti-PD-1 or anti-PD-L1). The goal is to see if adding Y-NM600 is safe and can make the immunotherapy work better. Up to 60 participants will b…

This early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This study is testing whether a lower dose of radiation can effectively treat metastatic tumors that have a specific genetic change called an ATM mutation. The goal is to find the smallest effective dose to reduce side effects. About 45 adults with advanced cancer and an ATM muta…

This first-in-human study tests an experimental oral drug called IDRX-42 in 278 adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check safety, find the right dose, and see if the drug can shrink tu…

This early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This study tests whether precise, high-dose radiation (stereotactic radiotherapy) can restore the effectiveness of anti-PD1 immunotherapy in patients with metastatic solid tumors. Participants are those who initially responded well to immunotherapy for at least 6 months but then …

This study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…

This study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while…

This early-stage trial tests whether combining high-intensity focused ultrasound (HIFU) with immune checkpoint inhibitors (ipilimumab and nivolumab) is safe and feasible for people with metastatic or unresectable cancer that has worsened after standard treatments. 24 adults will …

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase study tests a new treatment called PTC13, which uses specially engineered immune cells (CAR-T cells) to attack cancer cells that have a protein called CEA. The study includes 18 adults with advanced colorectal, stomach, pancreatic, or other solid tumors that have…

This phase 2 trial is testing a combination of two drugs—cabozantinib (a pill) and nivolumab (an infusion)—in 47 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The main goal is to see if the treatment can delay can…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This early-phase trial is testing a new approach for people with liver metastases (cancer that has spread to the liver from elsewhere). Doctors are using a procedure called TACE to deliver the drug bevacizumab directly into the liver's blood vessels, aiming to concentrate the tre…

This study tests a new radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target tumors using tiny particles. The main goals are to check safety, find the right dose, and see if it can s…

This study offers continued access to the cancer drug T-DXd for up to 50 people with advanced or metastatic cancer who are already benefiting from it in earlier trials. Researchers will monitor long-term safety, including serious side effects and reasons for stopping or reducing …

This study tests whether two common cancer immunotherapy drugs (nivolumab and pembrolizumab) can be given less often than the current standard schedule. About 264 adults with advanced or metastatic cancer will be randomly assigned to receive the drugs at standard intervals or ext…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…

This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. Th…

This early-stage trial is testing a new radioactive tracer called 68Ga-FXX489 (NNS309) for PET/CT scans. The goal is to see if it can safely and accurately detect tumors and their spread in 30 adults with suspected cancer. Researchers will measure how the tracer moves through the…

This study compares whole body diffusion-weighted MRI (DWI) to standard FDG PET/MRI scans in 30 adults with metastatic cancer. The goal is to see if DWI can spot cancer lesions as well as the PET scan, which uses a radioactive tracer. Participants will undergo both scans, and res…

This early-phase trial is testing whether a new radioactive tracer called 18F-Clofarabine (CFA) can be used in PET scans to measure an enzyme activity in cancer cells that may predict how well certain drugs like gemcitabine work. Four adults with metastatic cancer will receive th…

This study is testing whether a new MRI technique using a substance called hyperpolarized pyruvate gives consistent results in people with solid tumors. About 109 participants will have two special MRI scans to see if the images are reproducible. The goal is to improve how doctor…

This study tests whether three 15-minute hypnosis sessions can help people with persistent breathlessness from cancer, COPD, interstitial lung disease, or chronic heart failure feel more in control of their breathing. Researchers will measure changes using a standard questionnair…

This study looks at whether asking people with advanced cancer about their financial struggles each month can help reduce their worry and improve their quality of life. About 1,000 adults receiving treatment for advanced or metastatic cancer will be randomly assigned to either mo…

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…

This study tests a new type of radiation called proton GRID for people with large tumors (at least 4.5 cm) that cannot be removed by surgery or have spread. The goal is to safely relieve symptoms like pain. About 24 adults will receive three radiation treatments, and researchers …

This study compares a single, higher-dose palliative radiotherapy session to the usual 5-10 sessions for people with metastatic cancer. The goal is to see if one strong dose can keep symptoms away longer, up to 12 months. About 100 participants will be enrolled to measure how lon…

This study tests two support programs for parents with advanced cancer who have children aged 10 to 25. One program provides information and tips; the other adds exercises and emotional support. Researchers want to see which helps parents communicate better and feel more confiden…

This study tests the ApricityCare program, which helps people with metastatic cancer and their doctors spot treatment side effects early. The goal is to manage these side effects quickly so patients can stay on their cancer therapy longer. About 425 adults starting systemic cance…

This phase 3 trial is testing whether adding chaplain-provided spiritual care or psychotherapy/meditation to standard palliative care can improve survival and quality of life in people with advanced, non-curable cancer. About 854 participants with a life expectancy of one year or…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This observational study tracks over 10,000 people with advanced or metastatic cancer to understand why outcomes vary by race and background. Researchers collect social, genetic, and treatment data from patients at four cancer centers. The goal is to identify factors—like social …

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is testing a simple scoring system to predict whether people with metastatic cancer will survive at least 30 days after starting palliative radiation therapy. The score uses lab results, emergency room visits, and cancer type. About 214 adults will join to see if the t…

This registry is collecting information from 2,000 people with metastatic cancer who are receiving radiation therapy as part of their standard care. Researchers will gather clinical data and patient-reported outcomes to better understand how radiation affects cancer outcomes. The…

This pilot study is looking for better ways to see if endocrine therapy is working in people with a type of breast cancer called metastatic invasive lobular carcinoma. Researchers will use a special PET scan and blood tests to measure changes in estrogen signaling after 4 weeks o…

This study is testing whether a special smart shirt, called Hexoskin, can help monitor side effects in 100 patients receiving palliative radiotherapy for cancer that has spread. The shirt tracks heart rate, breathing, and activity levels. The goal is to see if it's practical to u…

This study looks at how much of the drug T-DXd enters brain tumors in people with HER2-positive brain cancers or glioblastoma. Thirty participants will receive T-DXd before surgery to remove a brain tumor, and researchers will measure drug levels in the tumor. The goal is to see …

This study is a registry that collects information from 300 adults with metastatic cancer who receive or have received a precise, high-dose form of radiation called ablative radiotherapy. The goal is to track short-term side effects and better understand the safety of this treatm…

This study is looking at whether analyzing the DNA of a patient's tumor can help doctors pick more effective treatments. Researchers will profile tumors from 100 adults with advanced, incurable cancer to see if they can find genetic changes that match existing drugs or clinical t…